Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease

Karar T. Shukur, Tugba Ercetin, Chiara Luise, Wolfgang Sippl, Okan Sirkecioglu, Mert Ulgen, Goknil P. Coskun, Mine Yarim, Mustafa Gazi, Hayrettin O. Gulcan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

A series of urolithin amide (i.e., URO-4–URO-10 and THU-4–THU-10) derivatives was designed and synthesized, and their chemical structures were confirmed with spectroscopic techniques and elemental analysis. The title compounds and synthesis intermediates (THU-1–THU-10 and URO-1–URO-10) were evaluated for their potential to inhibit acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase B (MAO-B). Compounds THU-4 and THU-8 were found to be the most potent inhibitors for the cholinesterases and MAO-B, respectively. The docking studies were also employed to evaluate the binding modes of the most active compounds with AChE, BuChE, and MAO-B. Furthermore, the moderate-to-strong activities of the compounds were also displayed in amyloid-beta inhibition and antioxidant assay systems. The results pointed out that the urolithin scaffold can be employed in drug design studies for the development of multitarget ligands acting on various cascades shown to be important within the pathophysiology of Alzheimer's disease.

Original languageEnglish
Article number2000467
JournalArchiv der Pharmazie
Volume354
Issue number5
DOIs
Publication statusPublished - May 2021

Bibliographical note

Publisher Copyright:
© 2021 Deutsche Pharmazeutische Gesellschaft

Keywords

  • Alzheimer's disease
  • amyloid beta
  • antioxidant
  • cholinesterase
  • MAO-B
  • urolithins

Fingerprint

Dive into the research topics of 'Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease'. Together they form a unique fingerprint.

Cite this